Table 1 Demographic and clinical characteristics of the NHANES samples and the ORION trials
Characteristic | ASCVD sample (n = 579) | Control one† (n = 781) | ASCVD-risk equivalent sample (n = 382) | Control two‡ (n = 98) |
|---|---|---|---|---|
Age — yr | 67 ± 10.2 | 66.4 ± 8.9 | 63.6 ± 11.5 | 62.7 ± 10.6 |
Male sex — no.(%) | 359(62)*** | 535(68.5) | 219(57.3) *** | 45(45.9) |
White race — no.(%) | 341(58.9) *** | 653(83.6) | 142(37.2) *** | 94(95.9) |
Cardiovascular risk factors — no.(%) | ||||
ASCVD | 579(100) | 781(100) | 0(0) | 0(0) |
Current smoker | 127(21.9) *** | 123(15.7) | 68(17.8) | 19(19.4) |
Hypertension | 438(75.7) *** | 714(91.4) | 264(69.1) | 67(68.4) |
Diabetes | 190(32.8) *** | 371(47.5) | 208(54.5) *** | 66(67.3) |
10-year predicted CVD risk ≥ 20% | / | / | 287(75.1) *** | 54(55.1) |
Lipid measures — mg/dL | ||||
LDL cholesterol | 103.2 ± 28 | 104.5 ± 39.6 | 128.8 ± 25.8*** | 143.1 ± 65.7 |
Total cholesterol | 181.6 ± 35.9 | 180.6 ± 46.1 | 210.2 ± 30.9*** | 232 ± 69.6 |
Non-HDL cholesterol | 131.2 ± 34.3** | 134 ± 44.5 | 158.6 ± 31.1*** | 177.9 ± 69.6 |
HDL cholesterol | 50.3 ± 14.3** | 46.6 ± 14.3 | 51.7 ± 13.7* | 50.3 ± 15.5 |
Triglycerides | 125 (87–175) | 127 (92–181) | 136 (95–188)*** | 159 (115–204) |